YahooSeptember 10, 2026 at 2:14 PM NYLast Month
Biohaven Stock Is Sinking. Epilepsy Drug Trial Roadblock Is Only the Latest Blow.
Biohaven says regulators placed a partial hold on a clinical study for its epilepsy drug candidate, opakalim. One rival drugmaker stands to benefit.
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
